Nifty’s Short-Term Bottom Likely In Place: Is It Time To Go Long?
The Nifty 50 snapped its eight-day losing streak, closing decisively above the 24,800 mark. Is this a sign of a short-term bottom, and should Indian investors consider going long?
Your blog category
The Nifty 50 snapped its eight-day losing streak, closing decisively above the 24,800 mark. Is this a sign of a short-term bottom, and should Indian investors consider going long?
Oil prices are on track for their largest weekly decline since late June, as the OPEC+ meeting is expected to lead to an increase in oil supply, exacerbating concerns of oversupply in the market.
The Indian stock market witnessed a significant turnaround on Wednesday, with the Nifty and Sensex snapping their 8-day losing streak. Get the latest updates on the market trends, Q2 results, and major corporate actions.
Tata Capital Ltd. is set to launch its initial public offering (IPO) on October 6, 2025, with a price band of Rs 310-326 per share. Here’s everything you need to know about the upcoming public issue.
Indian Overseas Bank (IOB) has announced a waiver of penal charges for non-maintenance of Minimum Average Balance in its Saving Account (SB-Public), effective October 1, 2025.
Get the latest updates on the Glottis IPO, including its day 2 subscription status, grey market premium, and other essential details for Indian investors.
Foreign portfolio investors (FPIs) have extended their selling streak in the Indian stock market, offloading equities worth Rs 2,327 crore. What does this mean for domestic investors and the overall market sentiment?
Get the latest updates on the Advance Agrolife IPO, including subscription details, GMP, and other key information for Indian investors.
Get the latest updates on the Royal Challengers Bangalore sale speculations and its potential impact on the Indian stock market, including insights from former IPL Chairman Lalit Modi and potential buyer Adar Poonawalla.
Pfizer Inc. has secured a three-year reprieve from the tariffs on pharmaceutical imports imposed by US President Donald Trump. Here’s what Indian investors need to know about the deal and its implications on the pharmaceutical sector.